Research programme: CNS disorder therapeutics - NB Health Laboratory

Drug Profile

Research programme: CNS disorder therapeutics - NB Health Laboratory

Alternative Names: P 005

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NB Health Laboratory
  • Class Small molecules
  • Mechanism of Action Casein kinase Idelta inhibitors; Casein kinase Iepsilon inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Alzheimer's disease; Insomnia; Somnambulism

Most Recent Events

  • 13 Sep 2016 Early research in Somnambulism in Japan (unspecified route) (NB Health laboratory website, September 2016)
  • 13 Sep 2016 NB Health laboratories has patent protection for P 005 in Japan, Europe and USA (NB Health Laboratories pipeline, September 2016)
  • 13 Sep 2016 Research programme: CNS disorder therapeutics - NB Health Laboratory is available for licensing as of 13 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top